Published in Managed Care Business Week, June 20th, 2006
Study 1: Coronary restenosis is prevented by the tyrosine kinase inhibitor (TKI) SU11218.
According to a study from Canada, "The aim of this study was to delineate the temporal profile of adventitial microvessel (Ad-MV) formation after stenting, its relationship to arterial wall hypoxia, and the effects of a TKI, SU11218, on Ad-MV and in-stent intimal hyperplasia (IH)."
"Adventitial microvessels have been reported after arterial injury; however, the underlying stimulus for this response and its relationship to IH is unknown," wrote .N. Cheema and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week